摘要
目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(rhTNFR:Fc)治疗甲状腺相关性眼病(TAO)的临床疗效及安全性。方法 TAO患者40例随机均分为两组,分别予rhTNFR:Fc(A组)和甲泼尼龙(B组)治疗12周,比较两组治疗前后临床活动度评分(CAS)及突眼度的变化;检测血清细胞因子水平,记录两组患者不良反应发生情况。结果与治疗前相比,治疗后两组患者CAS、血清IL-6及TNF-α水平均降低(P<0.05),而突眼度变化和血清IL-2水平差异无统计学意义(P>0.05)。治疗后A组血清TNF-α水平低于B组(P<0.05)。A组和B组分别有6例和10例发生不良反应(P>0.05)。结论 rhTNFR:Fc治疗TAO患者疗效确切,可作为治疗TAO的新选择。
Objective To explore the efficacy and safety of recombinant human tumor necrosis factor receptor-Fc fusion protein（rhTNFR：Fc）in the treatment of the patients with thyroid-associated ophthalmopathy（TAO）.Methods A total of 40 TAO patients was equally divided into two groups of A（treated with rhTNFR：Fc for 12 weeks）and B（treated with methylprednisolone for 12 weeks）.Before and after treatment,the changes of clinical activity scores（CAS）and exophthalmos were measured and seurm levels of TNF-α,IL-2and IL-6were detected.The adverse effects were observed.Results Compared with before,the CAS,serum levels of IL-6and TNF-αafter treatment were lower（P〈0.05）.The changes of exophthalmos and serum level of IL-2 after treatment were not significantly different in two groups between before and after treatment（P〈0.05）.Serum level of TNF-αafter treatment was lower in group A than that in group B（P〈0.05）.The adverse effects were seen in 6cases in group A and 10 cases in group B（P〈0.05）.Conclusion rhTNFR：Fc is effective in the treatment of TAO and may be taken as a new choice for TAO.
出处
《江苏医药》
CAS
2016年第9期1004-1006,共3页
Jiangsu Medical Journal
基金
国家自然科学基金(81102032)
